Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients

Simple item page
dc.contributor.advisorDandara, Colleten_ZA
dc.contributor.authorSwart, Marelizeen_ZA
dc.date.accessioned2015-01-09T08:56:56Z
dc.date.available2015-01-09T08:56:56Z
dc.date.issued2011en_ZA
dc.descriptionIncludes abstract.en_ZA
dc.descriptionIncludes bibliographical references (leaves 82-96).en_ZA
dc.description.abstractEfavirenz (EFV) is used in first-line antiretroviral (ARV) therapy of HIV-infected patients, and is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug transporter ABCB1. Genetic variability in the above genes may contribute to differences in EFV plasma concentrations which affect the levels of viral suppression as well as development of side effects in patients. The aim of this project was to evaluate the effects of the different genetic polymorphisms on EFV plasma concentration levels in HIV/AIDS patients receiving first-line antiretroviral treatment (ART) containing EFV.en_ZA
dc.identifier.apacitationSwart, M. (2011). <i>Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients</i>. (Thesis). University of Cape Town ,Faculty of Health Sciences ,Department of Medicine. Retrieved from http://hdl.handle.net/11427/11835en_ZA
dc.identifier.chicagocitationSwart, Marelize. <i>"Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients."</i> Thesis., University of Cape Town ,Faculty of Health Sciences ,Department of Medicine, 2011. http://hdl.handle.net/11427/11835en_ZA
dc.identifier.citationSwart, M. 2011. Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients. University of Cape Town.en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Swart, Marelize AB - Efavirenz (EFV) is used in first-line antiretroviral (ARV) therapy of HIV-infected patients, and is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug transporter ABCB1. Genetic variability in the above genes may contribute to differences in EFV plasma concentrations which affect the levels of viral suppression as well as development of side effects in patients. The aim of this project was to evaluate the effects of the different genetic polymorphisms on EFV plasma concentration levels in HIV/AIDS patients receiving first-line antiretroviral treatment (ART) containing EFV. DA - 2011 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2011 T1 - Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients TI - Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients UR - http://hdl.handle.net/11427/11835 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/11835
dc.identifier.vancouvercitationSwart M. Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients. [Thesis]. University of Cape Town ,Faculty of Health Sciences ,Department of Medicine, 2011 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/11835en_ZA
dc.language.isoengen_ZA
dc.publisher.departmentDepartment of Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.subject.otherMedicineen_ZA
dc.titlePharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patientsen_ZA
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationnameMScen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_hsf_2011_swart_m (1).pdf
Size:
3.15 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Masters